Page last updated: 2024-12-05

nalmefene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

nalmefene: RN given refers to 5-alpha isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5284594
CHEMBL ID982
CHEBI ID7457
SCHEMBL ID35230
MeSH IDM0116997

Synonyms (85)

Synonym
bdbm50045776
cid_5284594
revex (nalmefene hydrochloride)
(1s,5r,13s,17s)-4-(cyclopropylmethyl)-14-methylidene-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-triene-10,17-diol
gtpl1628
opvee (nalmefene hydrochloride nasal spray)
MLS000069366 ,
cervene
soberal
incystene
jf-1
alcofene
arthene
nalmetrene
orf-11676
selincro
cessal
nih-10365
revex
(5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol
nalmetrenum [inn-latin]
orf 11676
9a-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol
nalmefeno [inn-spanish]
nalmefenum [inn-latin]
morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5alpha)-
jf 1
hsdb 6761
nalmetreno [inn-spanish]
(5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol
17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol
nalmefene (usan/inn)
D05111
nalmefene
C08027
55096-26-9
smr000058884
PDSP2_001543
NCGC00021666-03
orf 1167
jkb-121
srd174
nalmefene hydrochloride hydrate
CHEMBL982 ,
chebi:7457 ,
srd-174
orf-1167
tox21_110873
cas-55096-26-9
dtxcid903347
dtxsid8023347 ,
HMS2232D07
nalmefenum
unii-tov02tdp9i
nalmetrenum
tov02tdp9i ,
nalmetreno
nalmefeno
nalmefene [usan:inn:ban]
nalmefene [hsdb]
nalmefene [inn]
nalmefene [mart.]
nalmefene [vandf]
nalmefene [who-dd]
nalmefene [mi]
nalmefene [usan]
SCHEMBL35230
NCGC00021666-04
tox21_110873_1
WJBLNOPPDWQMCH-MBPVOVBZSA-N
OPERA_ID_468
AB00384250_10
BCP16723
Q4353252
(4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylene-1,2,3,4,5,6,7,7a-octahydro-4ah-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DB06230
(1s,5r,13s,17s)-4-(cyclopropylmethyl)-14-methylidene-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-triene-10,17-diol
EN300-18384909
(4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
BN36715
nalmetrenum (inn-latin)
nalmefene (mart.)
nalmefeno (inn-spanish)
nalmefenum (inn-latin)
nalmetreno (inn-spanish)

Research Excerpts

Toxicity

Nalmefene is effective in the reversal of opiate overdose and appears to be safe in the management of patients with altered sensorium. No serious adverse events were judged to be related to nalmefenes.

ExcerptReferenceRelevance
" The drug was well tolerated by all subjects, and no clinically significant adverse effects were observed during the seven-day administration period."( Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist.
Dixon, R; Garg, D; Gentile, J; Howes, J; Hsiao, J; Hsu, HB; Weidler, D, 1987
)
0.27
" Nalmefene was well tolerated, with no serious adverse drug reactions."( A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
Goldberg, G; Mantero-Atienza, E; Mason, BJ; Morgan, RO; Ritvo, EC; Salvato, FR; Welch, B, 1994
)
0.29
" No serious adverse events were judged to be related to nalmefene."( Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study.
Kaplan, JL; Marx, JA, 1993
)
0.29
"Nalmefene is effective in the reversal of opiate overdose and appears to be safe in the management of patients with altered sensorium."( Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study.
Kaplan, JL; Marx, JA, 1993
)
0.29
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Most adverse events were mild or moderate, and transient; adverse events, including those leading to dropout, were more common with nalmefene."( Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
Gual, A; Mann, K; Sørensen, P; Torup, L; van den Brink, W, 2014
)
0.4
"7% on nalmefene in the total population had treatment-emergent adverse events (TEAEs)."( Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
Gual, A; Jensen, TJ; Mann, K; Strang, J; Sørensen, P; van den Brink, W, 2015
)
0.42
" This case should pinpoint our attention on this adverse event for a careful choice of anticraving therapy in patients with severe alcohol use disorder."( Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder.
Martelli, A; Mattioli, F; Milano, G; Natta, WM; Zavan, V, 2016
)
0.43
" Treatment-emergent adverse events during the study period were recorded and change from baseline in the number of heavy drinking days and total alcohol consumption were calculated."( Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Nakamura, I; Takahashi, M; Tsuneyoshi, K, 2020
)
0.56
"Overall, long-term nalmefene 20 mg was well tolerated; the main treatment-emergent adverse events reported in ≥5% of patients included nasopharyngitis (37."( Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Nakamura, I; Takahashi, M; Tsuneyoshi, K, 2020
)
0.56
" The most frequently reported adverse drug reactions (ADRs) were nausea (4."( Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies.
Andersohn, F; Borchert, K; Braun, S; Chick, J; Guillo, S; Haas, JS; Kuppan, K; Lemming, OM; Reines, EH; Toussi, M; Tubach, F, 2021
)
0.62

Pharmacokinetics

Terminal elimination half-life (t1/2) of nalmefene was prolonged in patients with ESRD. The aim of this study was to develop a population pharmacokinetic (PK) model.

ExcerptReferenceRelevance
" To determine the applicability of this method for human pharmacokinetic studies, nalmefene levels in plasma were measured at time points up to 24 h following oral and intravenous administration of 30 mg of nalmefene hydrochloride to two subjects."( Determination of nalmefene in plasma by high-performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies.
Albeck, H; Chou, JZ; Kreek, MJ, 1993
)
0.29
" The concentration-time data were analyzed by noncompartmental methods and subsequently linked to the pharmacodynamic effect data by a competitive antagonism link model."( Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparison.
Osifchin, E; Veng-Pedersen, P; Waters, SJ; Wilhelm, JA; Zakszewski, TB, 1995
)
0.29
"The opioid antagonist nalmefene was compared in its pharmacodynamic properties to the structurally similar antagonist naloxone in a 2 x 2 cross-over study with 8 dogs."( Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation.
Osifchin, E; Veng-Pedersen, P; Waters, SJ; Wilhelm, JA; Zakszewski, TB, 1995
)
0.29
" Terminal elimination half-life (t1/2) of both nalmefene and nalmefene glucuronide was prolonged in patients with ESRD compared with that in participants with normal renal function."( The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.
Alexander, AC; Dixon, R; Frye, RF; Johnston, J; Matzke, GR; Rault, RM; Reynolds, R, 1996
)
0.29
" The elderly volunteers also had a significantly shorter distributional half-life (t1/2 lambda 1) than young volunteers (0."( The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.
Bikhazi, GB; Frye, RF; Jallad, NS; Matzke, GR; Wilhelm, JA, 1996
)
0.29
" Concentration-time data were analyzed by a limited sampling strategy with adult pharmacokinetic parameters used as Bayesian priors."( Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study.
Chang, CT; Frye, RF; Gustafson, RA; Morris, JL; Nelson, ER; Rosen, DA; Rosen, KR; Steelman, RJ; Thackara, JW; Wilhelm, JA, 2000
)
0.31
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" After the single intravenous dose trial, 8 healthy volunteers received intravenous nalmefene at 2 mg once daily for 6 consecutive days, and the plasma drug concentrations were determined on the morning of days 4, 5 and 6 using liquid chromatography/tandem mass spectrometry and the pharmacokinetic parameters were calculated using PKS program."( [Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers].
Liao, RF; Wen, YG; Zeng, ZP, 2008
)
0.35
"The aims of this study were to develop a population pharmacokinetic (PK) model to describe the PK of nalmefene in healthy subjects and to relate the exposure of nalmefene to the μ-opioid receptor occupancy by simulations in the target population."( Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
Areberg, J; Faerch, KU; Kyhl, LE; Larsen, F; Li, S; Soegaard, B, 2016
)
0.43

Compound-Compound Interactions

Nalmefene Hcl combined with GA on the basis of the AIDL model has a significant effect on the awakening of GTS patients and can shorten sleep time.

ExcerptReferenceRelevance
"In order to study the clinical effect of sufentanil combined with nalmefene in fiberoptic bronchoscopy tracheal intubation in airway patients, a method based on sufentanil combined with nalmefene-assisted topical anesthesia for fiberoptic bronchoscopy-guided nasotracheal intubation method is proposed."( Effect of Sufentanil Combined with Nalmefene Assisted Surface Anesthesia on Transnasal Endotracheal Intubation Guided by Fiberoptic Bronchoscope.
Wang, Z; Zhan, Y; Zhang, J; Zhao, Z, 2022
)
0.72
"In this work, based on intelligent computing, the biological signals of patients were analyzed to investigate the hemodynamic changes and pulmonary complications of Nalmefene Hcl combined with general anesthesia (GA) in laparoscopic gynecological tumor surgery (GTS)."( Auto interpretable depth learning model to analyze the hemodynamic changes and pulmonary complications in laparoscopic gynecologic tumor surgery with nalmefene hydrochloride combined with general anesthesia.
Bai, B; Wang, LT; Wang, QQ; Zhang, AR, 2023
)
0.91
" Nalmefene Hcl combined with GA on the basis of the AIDL model has a significant effect on the awakening of GTS patients and can shorten sleep time."( Auto interpretable depth learning model to analyze the hemodynamic changes and pulmonary complications in laparoscopic gynecologic tumor surgery with nalmefene hydrochloride combined with general anesthesia.
Bai, B; Wang, LT; Wang, QQ; Zhang, AR, 2023
)
0.91

Bioavailability

Oral naltrexone and nalmefene have significantly more central nervous system (CNS) bioavailability than oral naloxone. Subcutaneous nalmfene was 3200- to 6400-fold more potent than oral Naltrexon.

ExcerptReferenceRelevance
"), a slowly metabolized, orally bioavailable opiate antagonist, with 30 times the potency of naloxone."( The effects of nalmefene, a potent oral opiate antagonist, on exercise-induced bronchospasm.
Christopher, MA; Harman, E; Hendeles, L; Wyzan, D, 1988
)
0.27
" Plasma concentration-time data for nalmefene indicate good oral bioavailability and a prolonged terminal elimination phase (mean t1/2 11."( Prolonged blockade of opioid effect with oral nalmefene.
DiFazio, CA; Dixon, R; Gal, TJ, 1986
)
0.27
" Oral naltrexone and nalmefene have significantly more central nervous system (CNS) bioavailability than oral naloxone."( Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig.
Culpepper-Morgan, JA; Holt, PR; Kreek, MJ; LaRoche, D, 1995
)
0.29
"Intravenous naloxone frequently ameliorates the pruritus of cholestasis, but its low oral bioavailability precludes its use as a long-term therapy."( Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study.
Alling, DW; Bergasa, NV; Jones, EA; Talbot, TL; Wells, MC, 1999
)
0.3
" Absolute oral bioavailability was estimated to 41% without food intake and with food about 53%."( Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
Areberg, J; Faerch, KU; Kyhl, LE; Larsen, F; Li, S; Soegaard, B, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Given the greater KOR potency and improved bioavailability compared to NTX, NMF may be a promising pharmacotherapeutic for cocaine use disorder (CUD)."( Nalmefene, a mu opioid receptor antagonist/kappa opioid receptor partial agonist, potentiates cocaine motivation but not intake with extended access self-administration in adult male mice.
Kreek, MJ; Morochnik, M; Reed, B; Windisch, KA, 2021
)
0.62
"25% (w/v) HP-β-CD, with absolute bioavailability of 76."( Effect of Different Absorption Enhancers on the Nasal Absorption of Nalmefene Hydrochloride.
Han, X; Li, M; Nie, G; Zhang, T; Zheng, A, 2022
)
0.72

Dosage Studied

Nalmefene has been shown to reverse opioid intoxication for as long as 8 h, reducing the need for continuous monitoring of intoxicated patients and repeated dosing of naloxone. Significant increases in ACTH and cortisol were observed after both antagonists, without an apparent dose-response relationship.

ExcerptRelevanceReference
" Butorphanol resulted in partial reversal of sedation at both dosage levels."( Reversal of oxymorphone sedation by naloxone, nalmefene, and butorphanol.
Anderson, GI; Doherty, T; Dyson, DH; McDonell, WN,
)
0.13
" To determine if these failures were due to inadequate dosage (pharmacokinetic failure) or lack of an inherent pharmacologic effect (pharmacodynamic failure), the present study was conducted with nalmefene (Key Pharmaceuticals, Inc."( The effects of nalmefene, a potent oral opiate antagonist, on exercise-induced bronchospasm.
Christopher, MA; Harman, E; Hendeles, L; Wyzan, D, 1988
)
0.27
" A dosing schedule of 20 mg q12h was then started and continued for seven days."( Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist.
Dixon, R; Garg, D; Gentile, J; Howes, J; Hsiao, J; Hsu, HB; Weidler, D, 1987
)
0.27
" Case descriptions highlight some of the many changes veterans experienced on nalmefene dosage increases."( A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder.
Glover, H, 1993
)
0.29
" Multiple venous blood samples were taken throughout the dosing regimen, and the resulting fentanyl, nalmefene, or naloxone plasma concentrations were determined."( Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparison.
Osifchin, E; Veng-Pedersen, P; Waters, SJ; Wilhelm, JA; Zakszewski, TB, 1995
)
0.29
" In rat, tissue distribution and metabolite plasma concentration-time data were obtained following intravenous bolus dosing of nalmefene."( Disposition of the opioid antagonist, nalmefene, in rat and dog.
Kvalo, LT; Lessor, RA; Mathur, C; Murthy, SS; Wilhelm, JA, 1996
)
0.29
" We conclude that no dosage alteration is warranted in elderly patients."( The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.
Bikhazi, GB; Frye, RF; Jallad, NS; Matzke, GR; Wilhelm, JA, 1996
)
0.29
" Determining the best dosing strategy has been the goal of recent treatment studies with alcohol-dependent patients."( Dosing issues in the pharmacotherapy of alcoholism.
Mason, BJ, 1996
)
0.29
" However, because nalmefene will be primarily used in the acute care setting for reversal of opioid-induced effects, it is not likely that these alterations will necessitate a dosage modification."( Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Dixon, R; Frye, RF; Matzke, GR; Rabinovitz, M; Schade, R, 1997
)
0.3
" Nalmefene has been shown to reverse opioid intoxication for as long as 8 h, reducing the need for continuous monitoring of intoxicated patients and repeated dosing of naloxone."( Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine.
Sternbach, G; Varon, J; Wang, DS,
)
0.13
" Significant increases in ACTH and cortisol were observed after both antagonists, without an apparent dose-response relationship; however, both doses of nalmefene resulted in greater HPA axis activation than either dose of naloxone (ACTH: p <0."( Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism.
Borg, L; Gunduz, M; Ho, A; King, A; Kreek, MJ; Maniar, S; Perret, G; Porter, M; Schluger, JH, 1998
)
0.3
" This study was designed to determine the dose-response relation for nalmefene for the prevention of morphine-related side effects in patients receiving intravenous patient-controlled analgesia."( Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia.
Chehade, J; Duffy, L; Gajraj, N; Johnson, ER; Joshi, GP; Wesevich, J, 1999
)
0.3
" The dose-response of intrathecal morphine (1-320 microg) for both scratching and antinociception in all subjects was established."( An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception.
Ko, MC; Naughton, NN, 2000
)
0.31
" Pretreatment with nalmefene (32 microg/kg subcutaneously) produced approximately 10-fold rightward shifts of intrathecal morphine dose-response curves for both behavioral effects."( An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception.
Ko, MC; Naughton, NN, 2000
)
0.31
" However, combined oral dosing of nalmefene and subthreshold doses of AM251, a cannabinoid CB1 receptor inverse agonist, led to a significant reduction in food intake in both lean and diet-induced obese (DIO) mice."( Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice.
Chen, RZ; Fong, TM; Huang, RR; MacNeil, DJ; Shen, CP, 2004
)
0.32
" Pharmacokinetics and mu-opioid receptor occupancy of nalmefene after single and repeated dosing over 7 days was studied in 12 healthy subjects."( Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
Aalto, S; Hagelberg, N; Hietala, J; Ingman, K; Juhakoski, A; Kallio, A; Karhuvaara, S; Någren, K; Oikonen, V; Scheinin, H, 2005
)
0.33
" The feeding adaptations were dissociable in onset, across individuals, and in their dose-response to the opioid-receptor antagonist nalmefene, suggesting that they represent distinct palatability-motivated processes."( Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food.
Cottone, P; Sabino, V; Steardo, L; Zorrilla, EP, 2008
)
0.35
"ICR mice were used to generate antagonist dose-response curves with intraperitoneal (i."( In vivo characterization of the opioid antagonist nalmefene in mice.
Bilsky, EJ; Giuvelis, D; Lowery, JJ; Osborn, MD; Skorput, AG, 2010
)
0.36
" These findings suggest that medication dosing may be an important consideration in achieving symptom control."( Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study.
Grant, JE; Hollander, E; Kim, SW; Odlaug, BL; Potenza, MN, 2010
)
0.36
"Nalmefene provides clinical benefit, constitutes a potential new pharmacological treatment paradigm in terms of the treatment goal and dosing regimen, and provides a method to address the unmet medical need in patients with alcohol dependence that need to reduce their alcohol consumption."( Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
Bladström, A; Gual, A; Mann, K; Torup, L; van den Brink, W, 2013
)
0.39
" This study provides evidence for the efficacy of nalmefene, which constitutes a new pharmacological treatment paradigm in terms of treatment goal (reduced drinking) and dosing regimen (as-needed), in alcohol dependent patients unable to reduce alcohol consumption on their own."( A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
Gual, A; He, Y; Mann, K; Torup, L; van den Brink, W, 2013
)
0.39
" Factors such as dosing frequency, potential adverse events, and availability of treatments may guide medication choice."( Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R, 2014
)
0.4
" As-needed dosage is a novel concept in the addictions field, which may overcome limitations of traditional regimens."( Nalmefene and its use in alcohol dependence.
Bruguera, P; Gual, A; López-Pelayo, H, 2014
)
0.4
"0ng/mL for a one-month period when dosed intramuscular to dogs or minipigs."( Lipophilic nalmefene prodrugs to achieve a one-month sustained release.
Annaert, PP; Atack, JR; Borghys, H; de Vries, R; De Zwart, LL; Embrechts, RC; Gaekens, T; Guillaume, M; Herdewijn, P; Leysen, JE; Megens, AA; Vermeulen, A, 2016
)
0.43
" Nalmefene provides a clinical benefit, constitutes a potential pharmacological treatment paradigm in terms of the treatment goal and dosing regimen, and addresses an unmet medical need in patients with alcohol dependence who need to reduce their alcohol consumption."( [Four cases of alcoholic liver cirrhosis in alcohol-dependent patients treated with nalmefene].
Tamaki, K, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
morphinane alkaloidAn isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency5.01190.00308.794948.0869AID1347053
GLS proteinHomo sapiens (human)Potency20.48390.35487.935539.8107AID624170
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.23910.000214.376460.0339AID720691
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.84930.000229.305416,493.5996AID743079
cytochrome P450 2D6Homo sapiens (human)Potency2.75400.00108.379861.1304AID1645840
polyproteinZika virusPotency5.01190.00308.794948.0869AID1347053
gemininHomo sapiens (human)Potency0.01300.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency16.13660.005612.367736.1254AID624032
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency100.00000.00419.962528.1838AID2675
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.89130.009610.525035.4813AID1479145
TAR DNA-binding protein 43Homo sapiens (human)Potency12.58931.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
kappa-type opioid receptor isoform 1Homo sapiens (human)IC50 (µMol)0.63950.00322.673715.6000AID1778; AID2136
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Mu-type opioid receptorHomo sapiens (human)Ki0.00060.00000.419710.0000AID1318760; AID317853; AID410718; AID450016
Delta-type opioid receptorHomo sapiens (human)Ki0.01300.00000.59789.9300AID1318762; AID317854; AID410719; AID450017
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.00200.00000.20186.4240AID223596
Kappa-type opioid receptorHomo sapiens (human)Ki0.00060.00000.362410.0000AID1318761; AID317855; AID410720; AID450018
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)31.50000.00132.612925.7000AID1966
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)31.50000.00133.394625.7000AID1966
Mu-type opioid receptorHomo sapiens (human)Kd0.00030.00010.18250.8300AID317858
Delta-type opioid receptorHomo sapiens (human)Kd0.00090.00040.51471.9800AID317859
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)31.50000.00133.394625.7000AID1966
Beta-galactosidaseEscherichia coliEC50 (µMol)31.500025.700025.700025.7000AID1966
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)Ke0.00030.00000.24883.0700AID317858
Delta-type opioid receptorHomo sapiens (human)Ke0.00100.00010.69799.0700AID317859
Kappa-type opioid receptorHomo sapiens (human)Ke0.00020.00000.35405.8100AID317860
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (107)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (44)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (136)

Assay IDTitleYearJournalArticle
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID317859Activity at human delta opioid receptor by [35S]GTPgammaS binding assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID222967Dose required to produce equivalent antagonism of morphine activity after peroral administration of compound1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine.
AID317868Inhibition of CYP2D6 at 10 uM2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID223599Antagonist activity towards U50 488 induced kappa opioid receptor by mouse writhing assay at 2.5 mg/kg subcutaneously1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
AID317867Inhibition of CYP2C19 at 10 uM2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID410718Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID222966Dose required to produce equivalent antagonism of morphine activity after intravenous administration of compound1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine.
AID450036Inhibition of human CYP2C9 at 10 uM2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID450020Selectivity ratio of Ki for kappa opioid receptor to Ki for mu opioid receptor2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID450048Inhibition of saccharin intake in Wistar rat at 12.5 mg/kg, sc by saccharin-self administration test2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID224576Antagonistic activity towards morphine induced mu-opioid receptor by mouse writhing assay at 1.25 mg/kg subcutaneously1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID223596Binding affinity towards kappa opioid receptor by displacement of [3H]EKC in guinea pig cortical tissue1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
AID624620Specific activity of expressed human recombinant UGT2B7H2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID176827Tested for concentration required to reduce the food consumption by 20 % subcutaneously1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID317861Metabolic stability assessed as half life in human liver microsomes at 40 uM2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID410720Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID317862Metabolic stability assessed as half life in mouse liver microsomes at 40 uM2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID410722Ratio of Ki for human delta opioid receptor to Ki for human kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID450043Inhibition of ethanol intake in Wistar rat at 6.25 ug/kg, sc by alcohol-self administration test2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID450016Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID317860Activity at human kappa opioid receptor by [35S]GTPgammaS binding assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID317857Selectivity ratio of Ki for human mu opioid receptor over Ki for human kappa opioid receptor2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID1318760Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.
AID450046Inhibition of ethanol intake in Wistar rat at 50 ug/kg, sc by alcohol-self administration test2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID450018Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID317854Displacement of [3H]DPDPE from human delta opioid receptor expressed in CHO cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID317866Inhibition of CYP2C9 at 10 uM2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID222965Dose required to produce equivalent antagonism of morphine activity after intracerebro ventricular administration of compound1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine.
AID317856Selectivity ratio of Ki for human mu opioid receptor over Ki for human delta opioid receptor2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID450039Inhibition of human CYP2C19 at 10 uM2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID624621Specific activity of expressed human recombinant UGT2B7Y2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID224587Binding affinity towards mu-opioid receptor by the displacement of [3H]Nal in rat brain homogenates1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
AID317853Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID450017Displacement of [3H]DPDPE from delta opioid receptor expressed in HEK293 cells by visible spectrophotometry2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID450019Selectivity ratio of Ki for delta opioid receptor to Ki for mu opioid receptor2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID410719Displacement of [3H]Naltrindole form human delta opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID317858Activity at human mu opioid receptor by [35S]GTPgammaS binding assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID317865Inhibition of CYP2B6 at 10 uM2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID450037Inhibition of human CYP3A4 at 10 uM2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID450040Inhibition of human CYP2D6 at 10 uM2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID450034Metabolic stability in mouse liver microsomes assessed as half life2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID317864Inhibition of CYP3A4 at 10 uM2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID450049Inhibition of saccharin intake in Wistar rat at 25 mg/kg, sc by saccharin-self administration test2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID317863Metabolic stability assessed as half life in human liver S9 fraction at 40 uM2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID450035Metabolic stability in human liver microsomes assessed as half life2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1318762Displacement of [3H]naltrindole from human delta-opioid receptor expressed in CHO cell membranes after 3 hrs by scintillation counting2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1318761Displacement of [3H]U69,593 from human kappa-opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.
AID410721Ratio of Ki for human mu opioid receptor to Ki for human kappa opioid receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
AID220524Binding affinity towards delta-opioid receptor by displacement of [3H]DADL in rat brain homogenates1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
AID450033Metabolic stability in rat liver microsomes assessed as half life2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID317871Inhibition of self alcohol consumption in rat using operant techniques2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID450044Inhibition of ethanol intake in Wistar rat at 12.5 ug/kg, sc by alcohol-self administration test2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID450047Inhibition of saccharin intake in Wistar rat at 6.25 mg/kg, sc by saccharin-self administration test2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID223601Antagonism of bremazocine induced kappa receptor diuresis in rats at a concentration of 0.08 mg/kg subcutaneously1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
AID450038Inhibition of human CYP2B6 at 10 uM2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID317855Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
AID450050Inhibition of saccharin intake in Wistar rat at 50 mg/kg, sc by saccharin-self administration test2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID450045Inhibition of ethanol intake in Wistar rat at 25 ug/kg, sc by alcohol-self administration test2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346361Human delta receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346329Human kappa receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1346364Human mu receptor (Opioid receptors)1998NIDA research monograph, Mar, Volume: 178Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (371)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (12.94)18.7374
1990's77 (20.75)18.2507
2000's59 (15.90)29.6817
2010's144 (38.81)24.3611
2020's43 (11.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials85 (22.08%)5.53%
Reviews66 (17.14%)6.00%
Case Studies17 (4.42%)4.05%
Observational3 (0.78%)0.25%
Other214 (55.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Outcomes From Injectable Nalmefene in the Emergency Department (COINED) [NCT05808881]Phase 40 participants (Actual)Interventional2023-06-30Withdrawn(stopped due to Due to changes in research objectives and methodological approach.)
Interventional, Open-label Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care [NCT02195817]Phase 4378 participants (Actual)Interventional2014-08-31Terminated(stopped due to The study was terminated due to enrolment challenges)
Nalmefene Challenge to Modulate Neural Reactivity to Alcohol-related and Emotional Cues in Non-treatment Seeking Alcohol Dependent Participants [NCT02372318]Early Phase 123 participants (Actual)Interventional2015-04-30Terminated(stopped due to Anticipated nr of 25 probands was not reached in terms of full data sets (missing data, low fMRI data quality), but time frame for recruitment ended.)
Exploratory, Interventional, Open-label, Fixed-dose Study With Selincro® As-needed Use, in Alcohol Dependent Patients With Liver Impairment [NCT02197598]Phase 445 participants (Actual)Interventional2014-09-30Completed
Two-Period, Two-Treatment, Randomized Crossover Study of the Pharmacokinetics of Nalmefene by Intranasal and Intramuscular Administration in Healthy Volunteers [NCT04759768]Phase 168 participants (Actual)Interventional2021-02-08Completed
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence [NCT00811941]Phase 3665 participants (Actual)Interventional2009-03-31Completed
Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation [NCT02639273]Phase 113 participants (Actual)Interventional2016-06-08Completed
Multicentre, Randomised, Double-blind, Placebo-controlled Trial of Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence. [NCT02824354]Phase 30 participants (Actual)Interventional2018-12-01Withdrawn(stopped due to no participants enrolled)
Open-label Trial on Therapeutic Effect and Tolerability of Nalmefene in Subjects With Alcohol Use Disorder and Comorbid Borderline Personality Disorder [NCT02752503]30 participants (Anticipated)Interventional2015-03-31Recruiting
Nalmefene Efficacy Study I: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, As-needed Use, in Patients With Alcohol Dependence [NCT00811720]Phase 3598 participants (Actual)Interventional2008-12-31Completed
Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study [NCT02934919]Phase 230 participants (Anticipated)Interventional2016-12-31Not yet recruiting
An Interventional, Single-site, Open-label, Four-group, Single-dose Study Investigating the Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment (Mild, Moderate, or Severe) and in Healthy Subjects [NCT01934166]Phase 132 participants (Actual)Interventional2013-07-31Completed
Interventional, Randomized, Double-blind, Cross-over, Placebo-controlled Study to Investigate the Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signal in the Ventral Striatum [NCT01969617]Phase 122 participants (Actual)Interventional2013-11-30Completed
Nalmefene Efficacy Study II: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, as Needed Use, in Patients With Alcohol Dependence [NCT00812461]Phase 3678 participants (Actual)Interventional2009-03-31Completed
A Two-part Open Label Study of the Pharmacodynamic Effects of Intranasal Nalmefene Compared to Intranasal Naloxone in Healthy Volunteers Under Steady State Opioid Agonism [NCT04828005]Phase 184 participants (Actual)Interventional2021-03-30Completed
Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons With Alcohol Problems [NCT03278886]Phase 1/Phase 211 participants (Actual)Interventional2018-07-03Completed
Patient Driven Recovery With Nalmefene and Coaching [NCT03279562]Phase 110 participants (Actual)Interventional2017-09-01Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling [NCT00132119]Phase 2/Phase 3233 participants (Actual)Interventional2005-08-31Completed
A Single Center Evaluation of Nalmefene HCl Versus Placebo on Smoking Cessation [NCT00202696]Phase 276 participants (Actual)Interventional2005-09-30Completed
Effects of Nalmefene and Baclofen on Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects: A Randomized, Placebo-controlled Study [NCT03034408]Phase 237 participants (Actual)Interventional2016-07-01Completed
A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence [NCT02382276]Phase 3405 participants (Actual)Interventional2015-07-13Completed
[NCT02679469]Phase 17 participants (Actual)Interventional2016-02-29Completed
The Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia in Patients Undergoing Gynecological Surgery [NCT03096730]150 participants (Actual)Interventional2017-02-06Completed
Nalmefene Hydrochloride Hydrate Tablets 10mg Specified Drug-use Results Survey (the Safety and the Prognosis After Achieving Reduced Alcohol Intake) [NCT04107051]533 participants (Actual)Observational2019-10-01Active, not recruiting
Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia [NCT04713358]Phase 4520 participants (Anticipated)Interventional2021-09-24Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial) [NCT02364947]Phase 3678 participants (Actual)Interventional2015-02-09Completed
NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions [NCT05540288]Phase 3266 participants (Anticipated)Interventional2023-03-31Recruiting
Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers [NCT03129347]Phase 114 participants (Actual)Interventional2017-06-01Completed
Use of Selincro and Impact on Usual Practice [NCT02492581]700 participants (Actual)Observational2016-02-29Completed
An Open-Label, Three-Period, Three-Treatment, Six-Sequence, Randomized Crossover Study of the Pharmacokinetics of Intranasal Nalmefene in Healthy Volunteers Using Three Dosing Regimens [NCT05219669]Phase 124 participants (Actual)Interventional2021-09-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00811720 (7) [back to overview]Change From Baseline in Clinical Status Using CGI-S
NCT00811720 (7) [back to overview]Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
NCT00811720 (7) [back to overview]Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
NCT00811720 (7) [back to overview]Change in Clinical Status Using the CGI-I
NCT00811720 (7) [back to overview]Drinking Risk Level (RSDRL) Response
NCT00811720 (7) [back to overview]Liver Function Test Alanine Aminotransferase (ALAT)
NCT00811720 (7) [back to overview]Liver Function Test Gamma-glutamyl Transferase (GGT)
NCT00811941 (16) [back to overview]Change From Baseline in Clinical Status Using CGI-S
NCT00811941 (16) [back to overview]Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
NCT00811941 (16) [back to overview]Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
NCT00811941 (16) [back to overview]Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
NCT00811941 (16) [back to overview]Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
NCT00811941 (16) [back to overview]Change in Clinical Status Using the CGI-I
NCT00811941 (16) [back to overview]Change in Clinical Status Using the CGI-I
NCT00811941 (16) [back to overview]Change From Baseline in Clinical Status Using CGI-S
NCT00811941 (16) [back to overview]Drinking Risk Level (RSDRL) Response
NCT00811941 (16) [back to overview]Liver Function Test Alanine Aminotransferase (ALAT)
NCT00811941 (16) [back to overview]Liver Function Test Alanine Aminotransferase (ALAT)
NCT00811941 (16) [back to overview]Liver Function Test Gamma-glutamyl Transferase (GGT)
NCT00811941 (16) [back to overview]Liver Function Test Gamma-glutamyl Transferase (GGT)
NCT00811941 (16) [back to overview]Percentage of Patients Who Withdrew Due to Intolerance to Treatment
NCT00811941 (16) [back to overview]Number of Patients With Adverse Events (AEs)
NCT00811941 (16) [back to overview]Drinking Risk Level (RSDRL) Response
NCT00812461 (7) [back to overview]Change From Baseline in Clinical Status Using CGI-S
NCT00812461 (7) [back to overview]Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
NCT00812461 (7) [back to overview]Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
NCT00812461 (7) [back to overview]Change in Clinical Status Using the CGI-I
NCT00812461 (7) [back to overview]Drinking Risk Level (RSDRL) Response
NCT00812461 (7) [back to overview]Liver Function Test Alanine Aminotransferase (ALAT)
NCT00812461 (7) [back to overview]Liver Function Test Gamma-glutamyl Transferase (GGT)
NCT02364947 (20) [back to overview]Response Shift Drinking Risk Level (RSDRL) at Week 12
NCT02364947 (20) [back to overview]Response Shift Drinking Risk Level (RSDRL) at Week 24
NCT02364947 (20) [back to overview]Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 24
NCT02364947 (20) [back to overview]70% TAC Responder Rate at Week 12
NCT02364947 (20) [back to overview]70% TAC Responder Rate at Week 24
NCT02364947 (20) [back to overview]Change in CGI-I From Baseline at Week 12
NCT02364947 (20) [back to overview]Change in CGI-I From Baseline at Week 24
NCT02364947 (20) [back to overview]Change in CGI-S From Baseline at Week 12
NCT02364947 (20) [back to overview]Change in CGI-S From Baseline at Week 24
NCT02364947 (20) [back to overview]Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 12
NCT02364947 (20) [back to overview]Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 24
NCT02364947 (20) [back to overview]Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 12
NCT02364947 (20) [back to overview]Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 24
NCT02364947 (20) [back to overview]Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12
NCT02364947 (20) [back to overview]Change in Total Alcohol Consumption (TAC) From Baseline at Week 12
NCT02364947 (20) [back to overview]Change in Total Alcohol Consumption (TAC) From Baseline at Week 24
NCT02364947 (20) [back to overview]HDD Responder Rate at Week 12
NCT02364947 (20) [back to overview]HDD Responder Rate at Week 24
NCT02364947 (20) [back to overview]Response Low Drinking Risk Level (RLDRL) at Week 12
NCT02364947 (20) [back to overview]Response Low Drinking Risk Level (RLDRL) at Week 24
NCT02382276 (3) [back to overview]Number of Participants With Adverse Events
NCT02382276 (3) [back to overview]Change in the Number of Heavy Drinking Days (HDDs) From Baseline
NCT02382276 (3) [back to overview]Change in Total Alcohol Consumption (TAC) From Baseline
NCT02679469 (3) [back to overview]Measure the Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t(AUCt)
NCT02679469 (3) [back to overview]Measure the Maximum (Peak) Plasma Concentration of the Drug (Cmax)
NCT02679469 (3) [back to overview]Measure the Terminal-phase Elimination Half-life (T1/2)
NCT03096730 (1) [back to overview]Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm
NCT03278886 (8) [back to overview]Adherence to Medication Defined as Self-report of Percentage of Study Medication Taken in the Past Two Weeks
NCT03278886 (8) [back to overview]Change in Alcohol Use Defined as a Change in the Mean Number of Grams of Pure Ethanol Consumed Per Day From Baseline to 8 Weeks
NCT03278886 (8) [back to overview]Medication Tolerability Measured Via a 0-100 Visual Analog Scale
NCT03278886 (8) [back to overview]Number of Participants With Adherence Assessed Via Riboflavin in the Urine Confirming Adherence
NCT03278886 (8) [back to overview]Severe Hepatotoxicity Defined as AST/ALT >10X the Level of Normal
NCT03278886 (8) [back to overview]Medication Satisfaction Defined as a Score From 0-100 Measured Via the Treatment Satisfaction Questionnaire for Medication (TSQM), With Higher Scores Corresponding to Higher Treatment Satisfaction.
NCT03278886 (8) [back to overview]Reported Side Effects Using a Symptom Checklist, Plus an Open-ended Question
NCT03278886 (8) [back to overview]Treatment Discontinuation Defined as Patient Self-report of Stopping Medication Anytime During the Treatment Period

Change From Baseline in Clinical Status Using CGI-S

The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). (NCT00811720)
Timeframe: Baseline and Week 24

Interventionunits on a scale (Mean)
Placebo-0.90
Nalmefene 18.06 mg-1.27

[back to top]

Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women. (NCT00811720)
Timeframe: Baseline and Month 6

Interventiondays (Mean)
Placebo-8.91
Nalmefene 18.06 mg-11.24

[back to top]

Change From Baseline in the Monthly Total Alcohol Consumption (TAC)

TAC was defined as mean daily alcohol consumption in g/day over a month (28 days). (NCT00811720)
Timeframe: Baseline and Month 6

Interventiong (Mean)
Placebo-39.70
Nalmefene 18.06 mg-50.66

[back to top]

Change in Clinical Status Using the CGI-I

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00811720)
Timeframe: Week 24

Interventionunits on a scale (Mean)
Placebo2.65
Nalmefene 18.06 mg2.30

[back to top]

Drinking Risk Level (RSDRL) Response

RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below. (NCT00811720)
Timeframe: Month 6

Interventionpercentage of participants (Number)
Placebo44.3
Nalmefene 18.06 mg36.9

[back to top]

Liver Function Test Alanine Aminotransferase (ALAT)

ALAT values (NCT00811720)
Timeframe: Week 24

InterventionIU/L (Geometric Mean)
Placebo28.1
Nalmefene 18.06 mg25.4

[back to top]

Liver Function Test Gamma-glutamyl Transferase (GGT)

GGT values (NCT00811720)
Timeframe: Week 24

InterventionIU/L (Geometric Mean)
Placebo45.7
Nalmefene 18.06 mg40.3

[back to top]

Change From Baseline in Clinical Status Using CGI-S

The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). (NCT00811941)
Timeframe: Baseline and Week 52

Interventionunits on a scale (Mean)
Placebo-1.08
Nalmefene 18.06 mg-1.30

[back to top]

Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 g for men and ≥40 g for women. (NCT00811941)
Timeframe: Baseline and Month 13

Interventiondays (Mean)
Placebo-8.96
Nalmefene 18.06 mg-10.53

[back to top]

Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women. (NCT00811941)
Timeframe: Baseline and Month 6

Interventiondays (Mean)
Placebo-8.92
Nalmefene 18.06 mg-9.80

[back to top]

Change From Baseline in the Monthly Total Alcohol Consumption (TAC)

TAC was defined as mean daily alcohol consumption in g/day over a month (28 days). (NCT00811941)
Timeframe: Baseline and Month 13

Interventiong (Mean)
Placebo-46.33
Nalmefene 18.06 mg-52.80

[back to top]

Change From Baseline in the Monthly Total Alcohol Consumption (TAC)

TAC was defined as mean daily alcohol consumption in g/day over a month (28 days). (NCT00811941)
Timeframe: Baseline and Month 6

Interventiong (Mean)
Placebo-45.58
Nalmefene 18.06 mg-49.05

[back to top]

Change in Clinical Status Using the CGI-I

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00811941)
Timeframe: Week 24

Interventionunits on a scale (Mean)
Placebo2.68
Nalmefene 18.06 mg2.54

[back to top]

Change in Clinical Status Using the CGI-I

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00811941)
Timeframe: Week 52

Interventionunits on a scale (Mean)
Placebo2.52
Nalmefene 18.06 mg2.26

[back to top]

Change From Baseline in Clinical Status Using CGI-S

The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). (NCT00811941)
Timeframe: Baseline and Week 24

Interventionunits on a scale (Mean)
Placebo-0.75
Nalmefene 18.06 mg-0.94

[back to top]

Drinking Risk Level (RSDRL) Response

RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below. (NCT00811941)
Timeframe: Month 6

Interventionpercentage of participants (Number)
Placebo63.5
Nalmefene 18.06 mg62.2

[back to top]

Liver Function Test Alanine Aminotransferase (ALAT)

ALAT values (NCT00811941)
Timeframe: Week 24

InterventionIU/L (Geometric Mean)
Placebo25.8
Nalmefene 18.06 mg25.6

[back to top]

Liver Function Test Alanine Aminotransferase (ALAT)

ALAT values (NCT00811941)
Timeframe: Week 52

InterventionIU/L (Geometric Mean)
Placebo27.8
Nalmefene 18.06 mg24.6

[back to top]

Liver Function Test Gamma-glutamyl Transferase (GGT)

GGT values (NCT00811941)
Timeframe: Week 24

InterventionIU/L (Geometric Mean)
Placebo34.5
Nalmefene 18.06 mg32.2

[back to top]

Liver Function Test Gamma-glutamyl Transferase (GGT)

GGT values (NCT00811941)
Timeframe: Week 52

InterventionIU/L (Geometric Mean)
Placebo41.3
Nalmefene 18.06 mg32.0

[back to top]

Percentage of Patients Who Withdrew Due to Intolerance to Treatment

(NCT00811941)
Timeframe: Baseline to Week 52

Interventionpercentage of participants (Number)
Placebo1.2
Nalmefene 18.06 mg8.6

[back to top]

Number of Patients With Adverse Events (AEs)

Overview of AEs (NCT00811941)
Timeframe: Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks.

,
Interventionparticipants (Number)
Patients with AEsPatients with Serious AEs (SAEs)Patients with AEs Leading to Withdrawal
Nalmefene 18.06 mg3773557
Placebo10385

[back to top]

Drinking Risk Level (RSDRL) Response

RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below. (NCT00811941)
Timeframe: Month 13

Interventionpercentage of participants (Number)
Placebo54.0
Nalmefene 18.06 mg54.5

[back to top]

Change From Baseline in Clinical Status Using CGI-S

The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). (NCT00812461)
Timeframe: Baseline and Week 24

Interventionunits on a scale (Mean)
Placebo-1.04
Nalmefene 18.06 mg-1.27

[back to top]

Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)

Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women. (NCT00812461)
Timeframe: Baseline and Month 6

Interventiondays (Mean)
Placebo-10.58
Nalmefene 18.06 mg-12.30

[back to top]

Change From Baseline in the Monthly Total Alcohol Consumption (TAC)

TAC was defined as mean daily alcohol consumption in g/day over a month (28 days). (NCT00812461)
Timeframe: Baseline and Month 6

Interventiong (Mean)
Placebo-54.06
Nalmefene 18.06 mg-59.01

[back to top]

Change in Clinical Status Using the CGI-I

The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00812461)
Timeframe: Week 24

Interventionunits on a scale (Mean)
Placebo2.68
Nalmefene 18.06 mg2.51

[back to top]

Drinking Risk Level (RSDRL) Response

RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below. (NCT00812461)
Timeframe: Month 6

Interventionpercentage of participants (Number)
Placebo47.9
Nalmefene 18.06 mg45.6

[back to top]

Liver Function Test Alanine Aminotransferase (ALAT)

ALAT values (NCT00812461)
Timeframe: Week 24

InterventionIU/L (Geometric Mean)
Placebo27.2
Nalmefene 18.06 mg25.0

[back to top]

Liver Function Test Gamma-glutamyl Transferase (GGT)

GGT values (NCT00812461)
Timeframe: Week 24

InterventionIU/L (Geometric Mean)
Placebo44.9
Nalmefene 18.06 mg43.3

[back to top]

Response Shift Drinking Risk Level (RSDRL) at Week 12

Proportion of patients with a downward shift in drinking risk level of two categories or more (NCT02364947)
Timeframe: Week 12

Interventionpercentage (Number)
Nalmefene Hydrochloride 20 mg41.3
Nalmefene Hydrochloride 10 mg35.7
Placebo20.1

[back to top]

Response Shift Drinking Risk Level (RSDRL) at Week 24

Proportion of patients with a downward shift in drinking risk level of two categories or more (NCT02364947)
Timeframe: Week 24

Interventionpercentage (Number)
Nalmefene Hydrochloride 20 mg44.4
Nalmefene Hydrochloride 10 mg47.5
Placebo27.5

[back to top]

Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 24

(NCT02364947)
Timeframe: Week 24

Interventiondays/month (Least Squares Mean)
Nalmefene Hydrochloride 20 mg-13.25
Nalmefene Hydrochloride 10 mg-13.88
Placebo-9.33

[back to top]

70% TAC Responder Rate at Week 12

Proportion of patients with a 70% decrease in TAC (NCT02364947)
Timeframe: Week 12

Interventionpercentage (Number)
Nalmefene Hydrochloride 20 mg18.0
Nalmefene Hydrochloride 10 mg19.5
Placebo8.5

[back to top]

70% TAC Responder Rate at Week 24

Proportion of patients with a 70% decrease in TAC (NCT02364947)
Timeframe: Week 24

Interventionpercentage (Number)
Nalmefene Hydrochloride 20 mg23.8
Nalmefene Hydrochloride 10 mg23.4
Placebo10.8

[back to top]

Change in CGI-I From Baseline at Week 12

The CGI-I scale is used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse). (NCT02364947)
Timeframe: Week 12

Interventionunits on a scale (Least Squares Mean)
Nalmefene Hydrochloride 20 mg2.62
Nalmefene Hydrochloride 10 mg2.65
Placebo3.13

[back to top]

Change in CGI-I From Baseline at Week 24

The CGI-I scale was used to assess a patient's improvement (or worsening). The investigator or subinvestigator assesses a subject's condition relative to baseline on a 7-point scale ranging from 1 (Very much improved) to 7 (Very much worse). (NCT02364947)
Timeframe: Week 24

Interventionunits on a scale (Least Squares Mean)
Nalmefene Hydrochloride 20 mg2.49
Nalmefene Hydrochloride 10 mg2.44
Placebo2.99

[back to top]

Change in CGI-S From Baseline at Week 12

The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). (NCT02364947)
Timeframe: Week 12

Interventionunits on a scale (Least Squares Mean)
Nalmefene Hydrochloride 20 mg-0.60
Nalmefene Hydrochloride 10 mg-0.63
Placebo-0.34

[back to top]

Change in CGI-S From Baseline at Week 24

The CGI-S scale was used by clinicians when assessing their global impression of a patient's current clinical condition. The investigator or subinvestigator used his/her clinical experience with this patient population to rate the severity of a subject's clinical condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). (NCT02364947)
Timeframe: Week 24

Interventionunits on a scale (Least Squares Mean)
Nalmefene Hydrochloride 20 mg-0.75
Nalmefene Hydrochloride 10 mg-0.77
Placebo-0.41

[back to top]

Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 12

All-patients-randomised set (NCT02364947)
Timeframe: Week 12

InterventionIU/L (Least Squares Mean)
Nalmefene Hydrochloride 20 mg2.968
Nalmefene Hydrochloride 10 mg2.988
Placebo3.038

[back to top]

Change in Logarithm Scale in Serum Alanine Aminotransferase From Baseline at Week 24

All-patients-randomised set (NCT02364947)
Timeframe: Week 24

InterventionIU/L (Least Squares Mean)
Nalmefene Hydrochloride 20 mg2.971
Nalmefene Hydrochloride 10 mg2.987
Placebo3.036

[back to top]

Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 12

All-patients-randomised set (NCT02364947)
Timeframe: Week 12

InterventionIU/L (Least Squares Mean)
Nalmefene Hydrochloride 20 mg3.666
Nalmefene Hydrochloride 10 mg3.702
Placebo3.858

[back to top]

Change in Logarithm Scale in Serum γ-glutamyltransferase From Baseline at Week 24

All-patients-randomised set (NCT02364947)
Timeframe: Week 24

InterventionIU/L (Least Squares Mean)
Nalmefene Hydrochloride 20 mg3.663
Nalmefene Hydrochloride 10 mg3.692
Placebo3.831

[back to top]

Change in the Number of Heavy Drinking Days (HDDs) From Baseline at Week 12

The number of HDDs is defined as the number of days per month [days/month] with alcohol consumption of > 60 g for males and > 40 g for females (NCT02364947)
Timeframe: Week 12

Interventiondays/month (Least Squares Mean)
Nalmefene Hydrochloride 20 mg-12.25
Nalmefene Hydrochloride 10 mg-12.09
Placebo-7.91

[back to top]

Change in Total Alcohol Consumption (TAC) From Baseline at Week 12

(NCT02364947)
Timeframe: Week 12

Interventiong/day (Least Squares Mean)
Nalmefene Hydrochloride 20 mg-44.90
Nalmefene Hydrochloride 10 mg-45.36
Placebo-32.43

[back to top]

Change in Total Alcohol Consumption (TAC) From Baseline at Week 24

(NCT02364947)
Timeframe: Week 24

Interventiong/day (Least Squares Mean)
Nalmefene Hydrochloride 20 mg-49.43
Nalmefene Hydrochloride 10 mg-49.55
Placebo-38.28

[back to top]

HDD Responder Rate at Week 12

Proportion of patients with ≤4 HDDs (NCT02364947)
Timeframe: Week 12

Interventionpercentage (Number)
Nalmefene Hydrochloride 20 mg35.0
Nalmefene Hydrochloride 10 mg36.4
Placebo19.2

[back to top]

HDD Responder Rate at Week 24

Proportion of patients with ≤4 HDDs (NCT02364947)
Timeframe: Week 24

Interventionpercentage (Number)
Nalmefene Hydrochloride 20 mg33.9
Nalmefene Hydrochloride 10 mg44.0
Placebo25.2

[back to top]

Response Low Drinking Risk Level (RLDRL) at Week 12

Proportion of patients with low or lower drinking risk level (NCT02364947)
Timeframe: Week 12

Interventionpercentage (Number)
Nalmefene Hydrochloride 20 mg29.6
Nalmefene Hydrochloride 10 mg25.3
Placebo10.7

[back to top]

Response Low Drinking Risk Level (RLDRL) at Week 24

Proportion of patients with low or lower drinking risk level (NCT02364947)
Timeframe: Week 24

Interventionpercentage (Number)
Nalmefene Hydrochloride 20 mg29.6
Nalmefene Hydrochloride 10 mg32.6
Placebo17.6

[back to top]

Number of Participants With Adverse Events

(NCT02382276)
Timeframe: 24-week treatment period

InterventionNumber of participants (Number)
Nalmefene 20 mg in the lead-in Study96
Nalmefene 10 mg in the lead-in Study67
Placebo in the lead-in Study141

[back to top]

Change in the Number of Heavy Drinking Days (HDDs) From Baseline

(NCT02382276)
Timeframe: Week 24

Interventiondays/month (Least Squares Mean)
Nalmefene 20 mg in the lead-in Study-15.09
Nalmefene 10 mg in the lead-in Study-17.15
Placebo in the lead-in Study-16.35

[back to top]

Change in Total Alcohol Consumption (TAC) From Baseline

(NCT02382276)
Timeframe: Week 24

Interventiong/day (Least Squares Mean)
Nalmefene 20 mg in the lead-in Study-53.20
Nalmefene 10 mg in the lead-in Study-57.93
Placebo in the lead-in Study-55.77

[back to top]

Measure the Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t(AUCt)

(NCT02679469)
Timeframe: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose

Interventionng・h/mL (Mean)
Nalmefene Hydrochloride 10 mg61.8

[back to top]

Measure the Maximum (Peak) Plasma Concentration of the Drug (Cmax)

(NCT02679469)
Timeframe: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose

Interventionng/mL (Mean)
Nalmefene Hydrochloride 10 mg8.88

[back to top]

Measure the Terminal-phase Elimination Half-life (T1/2)

(NCT02679469)
Timeframe: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose

Interventionhours (Median)
Nalmefene Hydrochloride 10 mg12.1

[back to top]

Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm

The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament at 24 hours postoperatively (NCT03096730)
Timeframe: 24 hours after surgery

Interventiong (Mean)
Normal Saline61.5
Sufentanil88.2
Dexmedetomidine73.0
Nalmefene67.2
Dexmedetomidine-Nalmefene74.0

[back to top]

Adherence to Medication Defined as Self-report of Percentage of Study Medication Taken in the Past Two Weeks

Measured by participants' drawing a line on a a Visual Analog Scale, which ranges from 0 to 100. Higher numbers indicate higher adherence to study medication. (NCT03278886)
Timeframe: Endpoint at 8 weeks

Interventionscore on a scale (Mean)
Low Dose Naltrexone87.5
Nalmefene0

[back to top]

Change in Alcohol Use Defined as a Change in the Mean Number of Grams of Pure Ethanol Consumed Per Day From Baseline to 8 Weeks

Measured via 30 Day Alcohol Use Timeline Follow Back Method (NCT03278886)
Timeframe: Baseline, 8 weeks

Interventiongrams of ethanol (Mean)
Low Dose Naltrexone5.5
Nalmefene-6.83

[back to top]

Medication Tolerability Measured Via a 0-100 Visual Analog Scale

"Medication tolerability will be measured via a 0-100 visual analog scale. Participants will be asked to indicate on a scale of 0-100, how well they have tolerated the study medication with 0 anchored as cannot tolerate at all and 100 as tolerate perfectly well. Higher numbers will be indicative of higher tolerability of the medication." (NCT03278886)
Timeframe: Primary endpoint at 8 weeks

Interventionscore on a scale (Mean)
Low Dose Naltrexone90.7
NalmefeneNA

[back to top]

Number of Participants With Adherence Assessed Via Riboflavin in the Urine Confirming Adherence

Measured through visual inspection of the urine for the presence or absence of riboflavin using ultraviolet (UV) light at the long wave setting (33 mm) in a room with low ambient light. (NCT03278886)
Timeframe: Endpoint at 8 weeks

Interventionparticipants (Number)
Low Dose Naltrexone1
Nalmefene0

[back to top]

Severe Hepatotoxicity Defined as AST/ALT >10X the Level of Normal

Aminotransferase levels (AST/ALT) are tested to look for severe hepatotoxicity defined as AST/ALT > 10 times the level of normal. (NCT03278886)
Timeframe: Endpoint at 8 weeks

Interventionparticipants (Number)
Low Dose Naltrexone0
Nalmefene0

[back to top]

Medication Satisfaction Defined as a Score From 0-100 Measured Via the Treatment Satisfaction Questionnaire for Medication (TSQM), With Higher Scores Corresponding to Higher Treatment Satisfaction.

Measured via using the 14-item Treatment Satisfaction Questionnaire, which consists of 14 items that result in four domains: Effectiveness, Side Effects, Convenience and Global Satisfaction. Higher scores indicate greater satisfaction with medication. Assessed at 4 and 8 week study visits. (NCT03278886)
Timeframe: 4 weeks, 8 weeks

,
Interventionscore on a scale (Mean)
4-Weeks8-Weeks
Low Dose Naltrexone47.347.3
Nalmefene3.63.6

[back to top]

Reported Side Effects Using a Symptom Checklist, Plus an Open-ended Question

Measured via a 16-item symptom checklist with the option for participants to report any experienced side effects not on the checklist. Side effect severity is rated by trained research assessors. The checklist is asked at 2, 4, 6, and 8-week study visits. (NCT03278886)
Timeframe: 2 weeks, 4 weeks, 6 weeks, 8 weeks

,
Interventionnumber of side effects (Mean)
2-Weeks4-Weeks6-Weeks8-Weeks
Low Dose Naltrexone1.51.30.90
Nalmefene4.51.51.50

[back to top]

Treatment Discontinuation Defined as Patient Self-report of Stopping Medication Anytime During the Treatment Period

Measured via one question asking participants if they had discontinued medication since their last visit. Assessed at 4 and 8 week study visits. (NCT03278886)
Timeframe: 4 weeks, 8 weeks

,
Interventiontreatment discontinuations (Number)
4-Weeks8-Weeks
Low Dose Naltrexone11
Nalmefene12

[back to top]